Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria-Reference-Cited by-同舟云学术

Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria

Published:2021-09-30 Issue: Volume: Page:
ISSN:1552-5260
Container-title:Alzheimer's & Dementia
language:en
Short-container-title:Alzheimer's & Dementia

Author:

Franzen Sanne¹,Smith Jade Emily¹,den Berg Esther¹,Rivera Mindt Monica²³,Bruchem‐Visser Rozemarijn L.⁴,Abner Erin L.⁵⁶⁷,Schneider Lon S.⁸,Prins Niels D.⁹¹⁰,Babulal Ganesh M.¹¹¹²,Papma Janne M.¹

Affiliation:

1. Department of Neurology Erasmus MC University Medical Center Rotterdam the Netherlands

2. Department of Psychology and Latin American Latino Studies Institute Fordham University The Bronx New York USA

3. Department of Neurology The Icahn School of Medicine at Mount Sinai New York New York USA

4. Department of Internal Medicine Erasmus MC University Medical Center Rotterdam the Netherlands

5. Sanders‐Brown Center on Aging and Alzheimer's Disease Center University of Kentucky Lexington Kentucky USA

6. College of Public Health Department of Epidemiology University of Kentucky Lexington Kentucky USA

7. College of Public Health Department of Biostatistics University of Kentucky Lexington Kentucky USA

8. Keck School of Medicine of the University of Southern California Los Angeles California USA

9. Alzheimer Center Department of Neurology VU University Medical Center Amsterdam the Netherlands

10. Brain Research Center Amsterdam the Netherlands

11. Department of Neurology and Knight Alzheimer's Disease Research Center Washington University School of Medicine St. Louis Missouri USA

12. Department of Psychology University of Johannesburg Johannesburg South Africa

Funder

National Science Foundation

National Institutes of Health

BrightFocus Foundation

Alzheimer's Association

Publisher

Wiley

Subject

Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/alz.12433

Reference81 articles.

1. 2015 Alzheimer's disease facts and figures;Alzheimer's Association;Alzheimers Dement,2015

2. Alzheimer’s Disease In African Americans: Risk Factors And Challenges For The Future

3. The global prevalence of dementia: A systematic review and metaanalysis

4. Migration and dementia: A meta‐analysis of epidemiological studies in Europe;Selten J‐P;Psychol Med,2020

5. Race reporting and disparities in clinical trials on Alzheimer’s disease: A systematic review

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Racial and ethnic diversity in global neuroscience clinical trials;Contemporary Clinical Trials Communications;2024-02

2. Commentary on Greenberg et al., “Prescribing anti‐amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions” [Alzheimer's Dement. 2023; 9(4):e12426. doi.org/10.1002/trc2.12426];Alzheimer's & Dementia: Translational Research & Clinical Interventions;2024-01

3. Advances in amyloid-targeting monoclonal antibodies for Alzheimer’s disease: clinical and public health issues;Expert Review of Neurotherapeutics;2023-11-24

4. Including Socially Isolated Black, Older Old Adults (Aged 80 and Above) with and without Mild Cognitive Impairment in a Clinical Trial: Recruitment Strategies and Perspectives;Journal of Multidisciplinary Healthcare;2023-11

5. Biomarkers of Alzheimer’s disease in Black and/or African American Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants;Neurobiology of Aging;2023-11